General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-01 | 2024-03 | -0.04 | -0.01 | 0.03 | 75.00% |
2024-02-29 | 2023-12 | -0.04 | N/A | N/A | N/A |
2023-11-01 | 2023-09 | -0.02 | N/A | N/A | N/A |
2023-08-02 | 2023-06 | -0.02 | 0.02 | 0.04 | 200.00% |
2023-05-03 | 2023-03 | -0.01 | 0.02 | 0.03 | 300.00% |
2023-03-01 | 2022-12 | 0.01 | 0.02 | 0.01 | 100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-19 | Goldman Sachs | Upgrade | Sell | Sell |
2023-07-18 | Northland Capital Markets | Upgrade | Market Perform | Market Perform |
2023-01-05 | Jefferies | Upgrade | Hold | Buy |
2022-10-18 | SVB Leerink | Upgrade | Market Perform | |
2022-05-23 | Goldman Sachs | Upgrade | Sell | |
2022-05-05 | JP Morgan | Downgrade | Neutral | Underweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-30 | BERG AARON D. | Officer | 633.26K | Conversion of Exercise of derivative security |
2024-01-21 | HOLT PATRICK | Chief Executive Officer | 314.43K | Purchase |
2022-07-28 | KALB MICHAEL WAYNE | Chief Financial Officer | 337.31K | Conversion of Exercise of derivative security |
2024-01-30 | KETCHUM STEVEN B | Officer | 658.72K | Conversion of Exercise of derivative security |
2022-08-18 | MARKS JASON M | Officer | 21.92K | Conversion of Exercise of derivative security |
2023-02-20 | MIKHAIL KARIM | Chief Executive Officer | 283.51K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Kynam Capital Management, LP | 12.00M | 14.28M | 12.15% |
2023-06-29 | Morgan Stanley | 11.28M | 13.42M | 11.41% |
2023-06-29 | Eversept Partners, LP | 10.50M | 12.50M | 10.63% |
2023-06-29 | Tang Capital Management, LLC | 7.10M | 8.45M | 7.19% |
2023-06-29 | SCP Investment, LP | 6.50M | 7.74M | 6.58% |
2023-06-29 | DG Capital Management, LLC | 5.47M | 6.51M | 5.54% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Northern Lights Fd Tr-13D Activist Fd | 3.81M | 4.53M | 3.85% |
2023-06-29 | Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 585.00K | 696.15K | 0.59% |
2023-06-29 | Legg Mason Clearbridge Small Cap Value Fd | 531.07K | 631.97K | 0.54% |
2023-06-29 | Columbia Fds Var Ser Tr II-Columbia Var Port-Overseas Core Fd | 458.93K | 546.12K | 0.46% |
2023-05-30 | Columbia Fds Ser Tr-Columbia Overseas Value Fd | 315.88K | 369.58K | 0.32% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 214.39K | 250.83K | 0.22% |
Split | Date |
---|---|
0.1 : 1 | 2008-01-18 |
0.1 : 1 | 1998-10-19 |
Jordan’s yacht
Hey Mr Pipe Dream....how is that ode dive treating you now?
Shorts and longs know this is going up in September. When you see a drop.......buy, buy, buy!!!!
Fellow longs - all the Amarin trends are “sell the news”. Does this continue until label expansion? Manipulation at its best
Konstantinos is an idiot! MEMORIAL DAY IS A HOLIDAY IN THE US! 4 day work week moron!
Jordan, JT Pipe Dream and all other shorts.....any opinions on this article?
https://alphastocknews.com/amarin-amrn-stock-is-dipping-grab-the-discount/245/
I think Jordan is actually Frank Jr.
The typical target price seems to be the $51pps. Why would anyone think differently?
This could get really ugly tomorrow
Vescepa could cure cancer, diabetes and heart disease....but it won’t matter for PPS if a trade agreement is never reached - Morgan Stanley certainly thinks we could be in trouble
Gee - look what Seeking Alpha said - label expansion expected.
Amen James - well said
Can I ask an honest question of shorts like JT Pipe Dream and Jordan? Do you really think your depressing, crappy posts actually influence people to give up and sell? You both seem like intelligent, logical people who know the Seeking Alpha article is junk and was only released in response to the Priority Review as a last ditch effort to save shorts.
Obvious the Seeking Alpha BS article was written in response to the Priority Review approval to try and save the shorts. The stock is not going anywhere until BO. Shorts know it. Between $16.50 and $19.50 until BO.
Going to pull all my money out of the market. Amarin could cure heart disease, cancer and diabetes and this stock will still lose due to tariffs. Timing is everything and the timing of Amarin growth will be futile as market crashes.
MM’s will keep this between $16.50 and $19.50 until BO.
The best news in roughly 8 months and this stock can barely hold a $2.00 increase? Wow....BO should net us another $3pps
For people saying no buyout - how do you know what’s in the works? Are you the same bears who said no priority review? Please just stop posting with no backup.